23214-92-8 (阿霉素,(8S,10S)-10-{(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yloxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione)

阿霉素;羟基柔红霉素;亚法里亚霉素;羟基红比霉素;14-羟正定霉素;多柔比星;阿霉素,BR;阿霉素盐酸盐;多柔比星标准品;10-((3-氨基-2,3,6-三去氧-alpha-L-来苏-己吡喃基)氧)-7,8,9,10-四氢-6,8,11-三羟基-8-羟乙酰基-1-甲氧基-5,12-萘二酮;

Adriamycin;10-((3-Amino-2,3,6-trideoxy-alpha-L-lyso-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione;14-Hydroxydaunomycin;(8S-cis)-10-(3-Amino-2,3,6-Trideoxy-alpha-L-Lyxo-Hexopyranosyl)Oxy-7,8,9,10-Tetrahydro-6,8,11-Trihydroxy-8-(Hydroxyacetyl)-1-Methoxy-5,12-Naphthacenedione;adiblastine (hydrochloride salt);adriablastine (hydrochloride salt);adriablatina (hydrochloride salt);Adriacin;Adriacin (hydrochloride salt);Adriamycin PFS;Adriamycin PFS (hydrochloride salt);Adriamycin RDF;Adriamycin RDF (hydrochloride salt);Adriblastin;Adriblastina;Adriblastina (hydrochloride salt);adriblatina (hydrochloride salt);Doxorubicin;Doxorubicin hydrochloride (hydrochloride salt);Farmablastina (hydrochloride salt);Hydroxydaunomycin hydrochloride (hydrochloride salt);Hydroxydaunorubicin hydrochloride (hydrochloride salt);Rubex;Rubex (hydrochloride salt);(8S,10S)-10-(((2R,4S,5S,6S)-4-Amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracen;ADRIAMYCIN ,UP26 CP2005;Doxorubicin (Adriamycin, Dox,NSC 123127,14-Hydroxydaunomycin, 14-Hydroxydaunorubicine);[14C]-Doxorubicin;[3H]-Doxorubicin;adriamycine;Doxil;Hydroxydaunorubicin;(1S,3S)-3,5,12-Trihydroxy-3-(hydroxyac;(1S,3S)-3,5,12-Trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside;Hydroxydaunomycin hydrochloride;(8S,10S)-10-{(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yloxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione;AKOS015951330;EINECS 245-495-6;(1S,3S)-3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-(3-amino-2,3,6-tridesoxy-alpha-L-lyxo-hexopyranosid);CHEBI:28748;hydroxydaunomycin;NCGC00024415-35;EPIRUBICIN HYDROCHLORIDE IMPURITY, DOXORUBICIN- [USP IMPURITY];HMS2089H06;NCGC00024415-40;(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-9-glycoloyl-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-quinone;hydrochloride;BRD-K92093830-003-04-3;Prestwick2_000438;Probes1_000151;Doxorubicine;NCGC00024415-42;DOXORUBICIN (MART.);DOXORUBICIN [WHO-DD];NCGC00024415-38;(8S,10S)-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-8-GLYCOLOYL-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-1-METHOXY-5,12-NAPHTHACENEDIONE;DOXORUBICIN [INN];NSC123127;(7S,9S)-7-[(2R,4S,5S,6S)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-4-methoxy-6,9,11-tris(oxidanyl)-9-(2-oxidanylethanoyl)-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride;DAUNORUBICIN HYDROCHLORIDE IMPURITY D [EP IMPURITY];Adriblastina (TN);Doxorubicin (USAN/INN);doxorrubicina;BP-23114;(8S,10S)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione;Doxorubicinum (INN-Latin);1,2,3,4,6,11-hexahydro-4beta,5,12-trihydroxy-4-(hydroxyacetyl)-10-methoxy-6, 11-Dioxonaphthacen-1beta-yl-3-amino-2,3,6-trideoxy-alpha-l-lyxohexopyranoside;10-((3-Amino-2,3,6-trideoxy-D-lyxohexopyranosyl)oxy)-8-glycolcyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione;DOXORUBICIN [MI];AOJJSUZBOXZQNB-TZSSRYMLSA-N;Doxorubicinum;NCGC00024415-37;Q18936;(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside;5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-;Caelyx (liposomal doxorubicin);DOXORUBICIN [USAN];Prestwick1_000438;(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;DOXORUBICIN [MART.];Adriablastin;14-Hydroxydaunorubicine;(7S,9R)-7-[(2S,4S,5S,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;ThermoDox;(8S-cis)-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione;BSPBio_001031;Epirubicin hydrochloride impurity, doxorubicin-;EPIRUBICIN HYDROCHLORIDE IMPURITY C [EP IMPURITY];Valrubicin impurity, doxorubicin;VALRUBICIN IMPURITY, DOXORUBICIN [USP IMPURITY];BSPBio_000456;ADM;Doxorubicin-P4/D10 conjugate;Doxorubicin [USAN:INN:BAN];1392315-46-6;(8S,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione;(7S,9S)-7-[(4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;80168379AG;5,12-naphthacenedione, 10-((3-Amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro- 6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione;Doxorubicina (INN-Spanish);BRD-K92093830-003-25-8;BDBM32022;FI 106;Doxorubicin-hLL1 conjugate;(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride;EN300-120698;(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;Hydroxyl Daunorubicin;VALRUBICIN IMPURITY, DOXORUBICIN (USP IMPURITY);Prestwick0_000438;DM2;GTPL7069;Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120;UNII-80168379AG;NSC-759155;MLS000028393;Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74;C01661;DOXORUBICIN [HSDB];Doxorubicine (INN-French);(8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione;LMPK13050001;CHEMBL53463;L01DB01;(7S,9S)-7-[(4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;Prestwick3_000438;(8S,10S)-10-;5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-;(8S-cis)-10-[(3-Amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione;cid_443939;D03899;A816625;DTXCID301480;NCGC00024415-41;5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-;Doxorubicin-hLL1;GR-319;5,12-NAPHTHACENEDIONE, 10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(HYDROXYACETYL)-1-METHOXY-, (8S-CIS)-;ADR;BDBM22984;Adriamycin semiquinone;NDC 38242-874;NCI-C01514;HSDB 3070;H11954;BPBio1_000502;1,2,3,4,6,11-Hexahydro-4beta,5,12-trihydroxy-4-(hydroxyacetyl)-10-methoxy-6,11-dioxonaphthacen-1beta-yl-3-amino-2,3,6-trideoxy-alpha-L-lyxohexopyranoside;Doxorubicina;(7S,9S)-7-[[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride;Doxorubicina [INN-Spanish];NS00002473;Doxorubicine [INN-French];(1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside;(8S,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione;(8S,10S)-10-((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione;SPBio_002395;NSC-123127;23214-92-8;HY-15142A;DOXORUBICIN [VANDF];SMP1_000106;Probes2_000129;(8S-cis)-10-;Doxorubicinum [INN-Latin];(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione;Doxorubicin-P4/D10;CCRIS 739;DB00997;SCHEMBL3243;Hydroxyldaunorubicin;DTXSID8021480;NCGC00024415-61;(8S,10S)-10;NSC 123127;BRD-K92093830-003-33-2;BRD-K92093830-003-31-6;BRD-K92093830-003-30-8;

MFCD00869292

AOJJSUZBOXZQNB-TZSSRYMLSA-N

InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1

[H][C@@]1(O[C@H]2C[C@](O)(C(CO)=O)CC(C2=C3O)=C(O)C4=C3C(C5=C(OC)C=CC=C5C4=O)=O)O[C@@H](C)[C@@H](O)[C@@H](N)C1

245-495-6

临床用于急、慢性淋巴细胞白血病及实体性肿瘤的治疗。本品不良反应有骨髓抑制心肌毒性等。